Guidelines for Switching from Sertraline to Escitalopram

Tapering Sertraline

Gradual taper of sertraline over 1–2 weeks, reducing the dose in small increments, minimizes withdrawal effects in patients discontinuing therapy. 1, 2, 4
A practical taper schedule (example): reduce from a full dose to 75 % for 3–4 days, then to 50 % for 3–4 days, then to 25 % for 3–4 days before stopping. 5
All selective serotonin reuptake inhibitors (SSRIs) should be slowly tapered when discontinued to reduce the risk of discontinuation syndrome. 6, 5

Escitalopram should be started at a low dose (10 mg daily) after the sertraline taper is completed or during the final 2–3 days of taper when the sertraline dose is very low. 6, 5
When two serotonergic agents are used sequentially, the second agent must be initiated at a low dose and increased slowly. 1, 2, 3

Caution is required when switching between SSRIs because of the potential for serotonin syndrome. 1, 2, 4
Early monitoring (first 24–48 hours after any dosage change) is essential to detect serotonin syndrome, which may present with mental status changes (e.g., agitation, confusion), neuromuscular hyperactivity (tremor, hyperreflexia, rigidity), and autonomic hyperactivity (tachycardia, hypertension, diaphoresis). 1, 2, 3, 4
If serotonin syndrome is identified, all serotonergic agents should be stopped immediately and supportive care provided. 4

Patients undergoing a sertraline taper should be observed for withdrawal symptoms such as dizziness, fatigue, nausea, insomnia, sensory disturbances, anxiety, irritability, and agitation. 1, 2, 5

Escitalopram and sertraline demonstrate comparable efficacy for depression and anxiety, but escitalopram is associated with fewer drug‑interaction risks. 1, 3, 4
Among SSRIs, escitalopram has the minimal impact on CYP450 enzymes, resulting in a lower propensity for pharmacokinetic drug interactions. 1, 3, 4

Co‑administration of sertraline with monoamine oxidase inhibitors (MAOIs) is contraindicated because of a high risk of serotonin syndrome. 6, 5
During the switch, patient contact should be increased (e.g., weekly or more frequently) to promptly identify adverse events. 6